- Home
- NRIX vs ELE Comparison
NRIX vs ELE Comparison
Compare NRIX & ELE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRIX | ELE |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | Canada |
| Employees | N/A | 13 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | NRIX | ELE |
|---|---|---|
| Price | $15.88 | $21.58 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $29.46 | N/A |
| AVG Volume (30 Days) | ★ 844.9K | 385.5K |
| Earning Date | 05-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $76,987,000.00 | N/A |
| Revenue This Year | N/A | $150.47 |
| Revenue Next Year | $29.30 | $91.08 |
| P/E Ratio | ★ N/A | $255.64 |
| Revenue Growth | ★ 99.31 | N/A |
| 52 Week Low | $8.18 | $14.01 |
| 52 Week High | $22.50 | $26.96 |
Technical Indicators
Market Signals| Indicator | NRIX | ELE |
|---|---|---|
| Relative Strength Index (RSI) | 42.26 | 55.24 |
| Support Level | $15.62 | $18.83 |
| Resistance Level | $19.98 | $22.01 |
| Average True Range (ATR) | 0.78 | 1.40 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 36.46 | 70.69 |
Price Performance
Historical ComparisonAbout NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About ELE Elemental Royalty Corporation
Elemental Royalty Corp is engaged in exploration discovery, royalty generation, royalty acquisition, and strategic investments.